Pamrevlumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePamrevlumab
Drug Alias NameAnti-CTGF antibodyFG-3019
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionConnective tissue growth factor inhibitors
TargetsConnective tissue growth factor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diabetes Mellitus, Type 2Diabetes Mellitus +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesFibrogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim Pharma Gmbh & Co KgFibrogen IncFondazione Policlinico Universitario Agostino Gemelli Irccs +[4] 
Inactive CompaniesNa Pharma Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)Pancreatic Neoplasms
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes MellitusGlomerulosclerosis, Focal Segmental +[7] 

Other Information

ATC CodeN/A
Related LinksN/A